Results 121 to 130 of about 12,443,450 (160)

Homozygous Type II Hyperlipoproteinemia Treatment

JAMA, 1974
Dietary treatment was minimally effective in two children with homozygous type II hyperlipoproteinemia who had no evidence of atherosclerosis. Neither patient could tolerate cholestyramine resin in therapeutic doses. A partial ileal bypass operation was performed on each child, aged 10 and 8 years old.
openaire   +1 more source

Colestipol in familial type II hyperlipoproteinemia: A three‐year trial

Clinical Pharmacology & Therapeutics, 1976
Colestipol. a new bile acid sequestrant polymer. has been shown to lower the serum cholesterol level more than 30% in 13 patients with familial type 11 hyperlipoproteinemia. Placebo for 6 wk was followed by colestipol for periods up to 36 mo. A slight but not significant increase of serum triglyceride concentrations was observed during the first 18 mo.
C, Harvengt, J P, Desager
openaire   +2 more sources

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

The American Journal of Cardiology, 1986
Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction.
Jeffrey M. Hoeg, Martha B. Maher, Loren A. Zech, Kent R. Bailey, Richard E. Gregg, Karl J. Lackner, Silvia S. Fojo, Michael A. Anchors, Marina Bojanovski, Dennis L. Sprecher, H.Bryan Brewer   +10 more
openaire   +2 more sources

Mevinolin and Neomycin in the Treatment of Type II Hyperlipoproteinemia

1987
The reduction of elevated low-density lipoprotein (LDL) cholesterol concentrations in patients with type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents that may be of value in treating hypercholesterolemia are mevinolin and neomycin.
Jeffrey M. Hoeg, Martha B. Maher, Kent R. Bailey, Silvia S. Fojo, H. Bryan Brewer   +4 more
openaire   +1 more source

[Familial IgM deficiency and type II hyperlipoproteinemia].

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1978
It is reported on the common appearance of a hyperlipoproteinaemia type II after Fredrickson and of a selective insufficiency of IgM in a family. The two generations of a family which have been observed since three years show these disturbances in a 42-year-old patient and all his four children.
H, Storch, B, Kuklinski, H, Schwenke
openaire   +1 more source

Cholestyramine in Type II Hyperlipoproteinemia

Annals of Internal Medicine, 1973
R I, Levy, D S, Fredrickson, N J, Stone, D W, Bilheimer, W V, Brown, C J, Glueck, A M, Gotto, P N, Herbert, P O, Kwiterovich, T, Langer, J, LaRosa, S E, Lux, A K, Rider, R S, Shulman, H R, Sloan   +14 more
openaire   +2 more sources

[Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV].

Bollettino della Societa italiana di biologia sperimentale, 1983
Authors have evaluated pseudocholinesterase activity in patients with type IIa and type IV hyperlipoproteinemia. Significative correlation has been found between PCE and C in type IV hyperlipoproteinemia. Authors suggest PCE activity can be proposed as useful biochemical marker of hyperlipoproteinemia.
M R, Averna, G, Montalto, G B, Rini, G, Di Fede, M, Labisi, G, Marino, A, Notarbartolo   +6 more
openaire   +1 more source

Treatment of hyperlipoproteinemia type II with etofibrate.

International journal of clinical pharmacology and biopharmacy, 1980
Seven patients with hyperlipoproteinemia (HLP) type II (four patients with type II A and three patients with type II B), who were experienced to be resistant to hypolipidemic drugs, were treated for 6 months with etofibrate, a double-ester of nicotinic acid and clofibrinic acid, at a dose of 0.3 g t.i.d.
openaire   +1 more source

Early Diagnosis of Familial Type II Hyperlipoproteinemia

Annals of Nutrition and Metabolism, 1973
H, Greten, H, Wengeler, H, Wagner
openaire   +2 more sources

[Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. II. Results of the treatment in relation to the type of hyperlipoproteinemia].

Przeglad lekarski, 1991
After three months of beclobrate treatment (100 mg once daily) of 63 patients with primary hyperlipoproteinemia (HLP) significant decrease of total cholesterol concentration was found in type IIa by 12.9%, IIb by 23.7%, IV by 20.8%. LDL cholesterol concentration decreased in type IIa by 15.4%, IIb by 8.3%, in type IV non significant increase of LDL ...
J, Sznajd, B, Idzior-Waluś, G, Korzus, J, Zabiński, A, Hebda, M, Markiewicz   +5 more
openaire   +1 more source